FDA says Abraxis failed to proactively address repeat media fill contamination issues
Regulatory NewsJoanne S. Eglovitch
BiotechnologyChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy